NCT03519737: An overdue trial by Cerevast Medical, Inc.
This trial is overdue. It was due to report 3 years, 8 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT03519737 |
|---|---|
| Title | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Aureva Transcranial Ultrasound Device With Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke (TRUST) |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 17, 2018 |
| Completion date | Nov. 30, 2021 |
| Required reporting date | Nov. 30, 2022, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 11, 2026 |
| Days late | 1350 |